Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.

Glycine, an amino acid, is used as a stabilizer. GAMMAGARD LIQUID does not contain sucrose.

GAMMAGARD LIQUID is made from human plasma. It may carry a risk of transmitting infectious agents, viruses, and theoretically, the Creutzfeldt- Jakob disease (CJD) agent.

Components used in the packaging of this product are latex-free.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Various mild and moderate reactions, such as headache, fever, fatigue, chills, flushing, dizziness, urticaria, wheezing or chest tightness, nausea, vomiting, rigors, back pain, chest pain, muscle cramps, and changes in blood pressure may occur with infusions of Immune Globulin Intravenous (Human).

For full prescribing information, please visit http://www.gammagardliquid.com.

GAMMAGARD S/D [Immune Globulin Intravenous (Human)]

GAMMAGARD S/D is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congeni
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 17, 2010 The oncology therapeutic area continues to ... the bio-pharmaceutical sector. It,s in this competitive environment that ... and tactics to support market education. To ... that companies inform thought leaders, physicians, patients and payers ...
... Tenn., Dec. 17, 2010 eTransX recently unveiled ... Messaging and Integration Engine), its application integration engine. ... it easy to integrate disparate healthcare information systems. ... performance improvements through 64-Bit computing and enhancements that ...
Cached Medicine Technology:Research from Best Practices, LLC Delivers Effective Market Education Tactics and Strategies for New Oncology Products 2eTransX Unveils Latest Version of Its eTX HEMI 2
(Date:8/21/2014)... 21, 2014 The City of Garden ... entertainment and programming for its inaugural “Re:Imagine Garden Grove ... 12, 2014, from 11 a.m. to 4 p.m., 2.85-miles ... cars and the downtown will be filled with diverse ... Community Arts Resources (CARS), for all to enjoy. , ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Among seniors, dimming ... The study involved more than 2,500 people, aged 65 ... study and again two, six and eight years later. ... the person,s risk of death during the study period, the ... effect, researchers led by Sharon Christ of Purdue University in ...
(Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... have felt elated using the tanning beds and cannot seem ... the elation than just the look good factor of the ... , have researched the background of the ‘feel good’ ... tan could also be igniting euphoric sensations, akin to the ...
... Jerry Mendell a neurologist, co-director of the Muscular ... professor of pediatrics, neurology and pathology at Ohio ... the Neuromuscular Research Program and Gene Therapy Center ... injection of Asklepios Biopharmaceutical Inc (AskBio’s) Biostrophin, which ...
... 570,000 children under the age of 15 die of AIDS ... - states a new global report highlighting concerns about the ... the World Health Organization (WHO) and the Joint United Nations ... HIV ART in low- and middle- income countries more than ...
... Rayburn, a cardiologist from the University of Alabama, Birmingham, told ... the drug showed no significant difference in the rate of ... or placebos. The drug Vioxx is produced and marketed by ... told a jury that the studies, covering a total of ...
... At fairing well in examining the heart and making ... They fair better than medical students, residents, and other ... in accurately identifying abnormal heart sounds. This was revealed ... Archives of Internal Medicine. ,The study was performed ...
... A new study has found that smoking and drinking at ... has exposed the adverse effects of tobacco and alcohol has ... second leading cause of cancer deaths, and doctors generally recommend ... Typically, the disease is diagnosed in people in their late ...
Cached Medicine News:Health News:Wider Addictive Choices – Now, Tanned Addicts 2Health News:Trial Of DMD Gene Therapy Initiated At Ohio 2Health News:AIDS Deaths On The Rise Due To Low Access To Antiretroviral Treatment 2Health News:Could Long Tern Vioxx Users Suffer From Heart Attacks? 2